clinical trials

News

MindMed gets FDA breakthrough tag for LSD in anxiety

In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120

News

GSK scores again with Blenrep in multiple myeloma

GSK continues to build the case for its multiple myeloma therapy Blenrep, which was pulled from the US market last year, with another positive phase 3 trial.

News

HIV, the AIDS virus (yellow), infecting a human cell

Gilead and MSD say weekly oral therapy controls HIV

Reducing the burden of treatment for people with HIV has been a key objective for drug developers since antiretroviral therapy (ART) first reached the market.

News

Novo Nordisk looks set to add another string to Ozempic bow

Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabete

News

Cannabinoids show promise in acute migraine clinical trial

Inhaled cannabinoids have been shown to perform better than placebo in providing pain relief for people suffering from acute migraine, according to a new clinical trial.

R&D

This week in clinical trials: 5th Feb to 9th Feb 2024

In this clinical trial round-up, we look at life sciences research and development announced during the week of 5th to 9th February, from early-stage onwards.

MindMed gets FDA breakthrough tag for LSD in anxiety

GSK scores again with Blenrep in multiple myeloma

Gilead and MSD say weekly oral therapy controls HIV

Novo Nordisk looks set to add another string to Ozempic bow

Cannabinoids show promise in acute migraine clinical trial

This week in clinical trials: 5th Feb to 9th Feb 2024

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

clinical trials

Editor's Picks